Sansum Diabetes Research Institute’s Post

The findings suggest that resistance training may have potential benefits for individuals undergoing inelastic compression therapy for chronic venous disease, as it can improve the effectiveness of compression therapy by enhancing interface pressure and reducing venous hypertension during ambulation. More information can be found in the study titled: "Effects of lower limb muscle strengthening on interface pressure in older adults undergoing inelastic compression: Randomized controlled clinical trial", authored by: Eduardo Simões Da Matta, Giovanni Mosti, Vanessa Silva Da Corralo, Luciano Branco de Quadros, Clodoaldo Antônio De Sá The study can be accessed at: https://lnkd.in/eMhxKxBX You can find further scientific publications in our publication database: https://lnkd.in/gMeMFs_V Furthermore, our newsletter shares information regarding the latest scientific publications involving L&R products. To subscribe to the newsletter, please register via the following link: https://lnkd.in/efFC4_hZ #LRMed #MedicalCompression #Medicalscience #pubmed #Science

Latest figures out of the UK have found more than 6000 people are currently waiting for a kidney transplant, the highest level in 10 years, with experts concerned the number of people needing a kidney replacement will continue to rise due to increasing cases of type 2 diabetes. Proteomics International’s Managing Director Dr Richard Lipscombe highlighted how Australia can and should be learning lessons from UK’s kidney disease crisis in the December edition of Medical Forum Magazine, outlining the importance of developing diagnostic and prognostic tools to assist in the prevention and early diagnosis of this disease. Proteomics International are proud to play a role in the fight to reduce the negative impact of chronic kidney disease in type 2 diabetics. PromarkerD can predict disease onset up to four years in advance, enabling timely treatment before kidney function loss occurs. You can read Richard’s piece in full online at the Medical Forum Magazine - https://lnkd.in/g8cxtiVU You can read more about the latest figures out of the UK here - https://lnkd.in/gYiJUuJj #diabetes #kidneyhealth #Type2Diabetes #DiabeticKidneyDisease #PromarkerD #DiagnosticInnovation #prognostics #PIQ #EarlyDiseaseDetection #DiabetesManagement 

🔬 Lab Showcase Series: Discover Cutting-Edge Research with Herzig Lab! 🌟 Ever wondered how groundbreaking research can transform diabetes treatment? ✨ Dive into the pioneering work of Herzig Lab at Helmholtz Munich, led by Prof. Dr. Stephan Herzig, focusing on diabetic complications. 💉🔬 🧪 Key Focus Areas: 1️⃣ Investigating how glucose and lipid imbalances cause vascular damage in diabetes. 🔍 2️⃣ Unveiling the role of reactive metabolite species in worsening diabetic complications. 🧪⚠️ 3️⃣ Identifying new therapeutic targets for diabetes prevention through insulin sensitivity studies. 🩺🎯 4️⃣ Studying the impact of reactive metabolites on long-term complications. 🔬📊 Explore how their groundbreaking research is shaping the future of diabetes treatment! 🌐🔍🩺 Credits: 📽 Video: Smrutimayee Prusty 📝 Content: Aditi Manjare #LabShowcaseSeries #HerzigLab #HelmholtzMunich #DiabetesResearch #LifeScience #InnovativeScience #NGSF

Transform a 2D CaCO2 permeability and absorption assay to a 3D more physiologically relevant model by the addition of a mucus layer. Take a read of this publication & reach out if interested!

Have a read of this highly informative peer review article.

Excited to see the cover story in Vascular News is highlighting our recent open access systematic review and metaanalysis on the potential repurposing of drugs to treat AAA medically by PhD students Joachim Sejr Skovbo Kristensen, Mads Liisberg, Lytfi Krasniqi, Lasse Obel,  Egle Kavaliunaite and I (https://lnkd.in/dDUFsE9t). What a job they did: Of a total of 7,484 screened studies, 39 were included and 12 drug groups underwent meta-analyses. Metformin and statins were statistically significant in slowing AAA growth - even after exclusion of high bias risk studies by -0.73mm/year regarding metformin and -0.84mm/year regarding statins.  However with high levels of heterogeneity. Better studies are needed. Fortunately 4 RCTs on Metformin is upcoming, but RCTs on statins will probably never be performed of ethical reasons. To provide the highest achievable evidence level to convince those not prescribing it to all AAA patients, we need to stick to robust pharmacoepidemiologic studies as we did when we demonstrated that statins reduced the risk of rupture by 25% and 30d postoperative mortalit by 20% ( https://lnkd.in/d3pP-GBd).  

Transforming the way we approach fatty liver disease isn't just about better diagnostics—it's about redefining patient care for a healthier tomorrow. 🌟 The shift from NAFLD to MAFLD in medical terminology not only marks a pivotal change in our understanding but also highlights the critical role of metabolic dysfunction in this condition, underlining the importance of personalized treatment strategies. At Arrow Dx, we're not just diagnosing fatty liver disease early; we're tailoring interventions to individual metabolic profiles, pioneering a future where care is as unique as each patient's DNA. 🧬💡 This terminology change from NAFLD to MAFLD is not just semantic; it signifies a deeper comprehension of the disease and a more focused approach to treatment. Dive deeper into how biotech innovations are paving the way for personalized medicine in our latest blog. Read now: https://lnkd.in/edAvAiqc #FattyLiverDisease #PersonalizedMedicine #ArrowDxInnovation

Happy to share this leading edge article about Resmetirom for the treatment of MASH fibrosis. https://lnkd.in/dK5_2JBm. A perspective on biological insight and clinical implications.

Focus on a case report on MOBIDERM for fibrosis reduction. MOBIDERM FOR FIBROSIS REDUCTION: Use of a tissue mobilising compression system¹ Find out more about this case report (level of evidence: IV) now: https://ow.ly/TTc550ORGX8 Key takeaway: MOBIDERM bandages seem to help in reducing lymphostatic fibrosis and achieving further lymphedema volume reduction. If you have any questions about MOBIDERM, please reach out to our awesome clinical specialist Jenni Muscat ! (1) Pamela Hodgson, Marie-Eve Letellier, Katrin Schumann, Linda Henry — Journal of Lymphoedema (2011), Vol 6, No 2

Currently in clinical trials, senolytics are an exciting, potentially new class of therapies that target #senescent cells and could change the way we approach chronic and inflammatory diseases.     Our #senolytic agent is designed to target and clear senescent cells in diabetic retinas, allowing the damaged tissue to heal itself and potentially restoring vision for patients living with #DME. See our scientific approach and recent clinical data outlined in Nature’s article here: https://bit.ly/3QPwlcZ